Head-to-head evidence
Insulin Lispro vs ORMD-0801
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Lispro · Humalog
Marketed by Eli Lilly
NCT00551356 · Phase 3 · completed
The study was randomized and compared two active treatments, but it was open-label, enrolled 53 participants, and used a glucose-excursion measure rather than a hard clinical endpoint. Because the registry provides no results, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT06251635 (registry estimate)
ORMD-0801
Developed by Oramed
NCT04606576 · Phase 3 · terminated
This is a large, randomized, fully blinded, placebo-controlled trial using blood sugar control (A1C), the standard disease-defining measure for diabetes, as its primary endpoint, a well-designed setup for showing a real treatment effect. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2027 · NCT06731075 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Lispro's landscape · ORMD-0801's landscape